{"id":"W2164035913","doi":"10.1200/jco.2012.46.0543","title":"Phase III Randomized, Placebo-Controlled Study of Cetuximab Plus Brivanib Alaninate Versus Cetuximab Plus Placebo in Patients With Metastatic, Chemotherapy-Refractory, Wild-Type <i>K-RAS</i> Colorectal Carcinoma: The NCIC Clinical Trials Group and AGITG CO.20 Trial","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":125,"is_retracted":false,"has_abstract":true,"ca_institutions":"Hotel Dieu Hospital","funders":"National Health and Medical Research Council; Bristol-Myers Squibb; Centre Hospitalier Universitaire de Québec; National Cancer Institute; University of Toronto; Flinders University; Monash University; Peter MacCallum Cancer Centre; University of New South Wales; Medical Research Council; University of Ottawa; Queen's University; Amgen","keywords":"Medicine; Cetuximab; Internal medicine; Clinical endpoint; Placebo; Hazard ratio; Colorectal cancer; Oncology; Population; Phases of clinical research; Chemotherapy; Gastroenterology; Urology; Surgery; Cancer; Clinical trial; Confidence interval; Pathology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.02057069,0.0005575347,0.01246897,0.000243547,0.0001398967,0.00004433325,0.0003287099,0.0003884788,0.0001683741],"category_scores_gemma":[0.01566221,0.0002761071,0.001220866,0.0002906661,0.0009881468,0.000226479,0.000114851,0.001568199,0.000004998863],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004613152,"about_ca_system_score_gemma":0.001823696,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003675432,"about_ca_topic_score_gemma":0.0005450744,"domain_scores_codex":[0.9819146,0.007849547,0.008120363,0.000573912,0.001018274,0.000523334],"domain_scores_gemma":[0.9517732,0.039681,0.006804745,0.0003776764,0.0009047,0.0004586766],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9277554,0.02924744,0.01341925,0.00002246233,0.00760806,0.0002128007,0.001116364,0.000008362565,0.000008065091,0.00000516715,0.001525488,0.0190711],"study_design_scores_gemma":[0.772921,0.1999011,0.01995284,0.00005301671,0.0047515,0.0000222405,0.0012641,0.000276489,0.000004792798,0.00002523726,0.0006327967,0.0001948176],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9821627,0.0009137638,0.00001553737,0.001228194,0.002362078,0.01265432,0.00001768051,0.00001380624,0.0006319862],"genre_scores_gemma":[0.9971595,0.0006899997,0.0002377611,0.0006344902,0.00081533,0.0003093535,0.00001315876,0.00004901497,0.00009142505],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1706537,"threshold_uncertainty_score":0.9999691,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1050762737576454,"score_gpt":0.4537744715422363,"score_spread":0.3486981977845909,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}